Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars
1. Viatris announced positive Phase 3 results for XULANE LO contraceptive patch. 2. New meloxicam formulation showed significant pain relief in clinical trials. 3. First-quarter 2025 sales met expectations but reported an 11% decline. 4. Revenue impacted by FDA issues at Indore facility, projected $500 million loss. 5. Stock price increased by 10.2%, reflecting market optimism.